会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Morphing surfaces for the control of boundary layer transition
    • 用于控制边界层过渡的变形曲面
    • US09315259B1
    • 2016-04-19
    • US12455467
    • 2009-06-02
    • Beverley McKeonKaushik BhattacharyaMichael Ortiz
    • Beverley McKeonKaushik BhattacharyaMichael Ortiz
    • B64C21/10
    • B64C21/10Y02T50/166
    • A structure configured to modify its surface morphology between a smooth state and a rough state in response to an applied stress. In demonstrated examples, a soft (PDMS) substrate is produced, and is pre-strained. A relatively stiff overlayer of a metal, such as chromium and gold, is applied to the substrate. When the pre-strained substrate is allowed to relax, the free surface of the stiff overlayer is forced to become distorted, yielding a free surface having a roughness of less than 1 millimeter. Repeated application and removal of the applied stress has been shown to yield reproducible changes in the morphology of the free surface. An application of such morphing free surface is to control a boundary layer transition of an aerodynamic fluid flowing over the surface.
    • 一种构造成响应于施加的应力而在平滑状态和粗糙状态之间修改其表面形态的结构。 在示例的实施例中,生产软(PDMS)基材并且是预应变的。 将相对较硬的金属覆盖层(如铬和金)施加到基底上。 当预应变基底被松弛时,刚性覆盖层的自由表面被迫变形,产生粗糙度小于1毫米的自由表面。 已经显示重复施加和去除所施加的应力以产生自由表面形态的可重复变化。 这种变形自由表面的应用是控制流过表面的空气动力流体的边界层过渡。
    • 4. 发明申请
    • PROCESS FOR THE ISOLATION OF ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER
    • 分离用于治疗癌症的有机化合物的方法
    • US20130065932A1
    • 2013-03-14
    • US13416930
    • 2012-03-09
    • Chitra MandalBikas Chandra PalKaushik BhattacharyaSuman Kumar SamantaSayantani SarkarRanjita Das
    • Chitra MandalBikas Chandra PalKaushik BhattacharyaSuman Kumar SamantaSayantani SarkarRanjita Das
    • A61K31/407A61P35/00C07D491/052
    • A61K31/407A61K36/75A61K2236/39C07D491/052
    • The present invention relates to two main components, mahanine and mahanimbine (dehydroxy-mahanine) from Murraya koenigii for the treatment of glioblastoma and cervical carcinoma. Mahanimbine exhibited anti-cancer activity against lymphoid leukemia, myeloid leukemia, glioma, cervical carcinoma, pancreatic, colon and lung cancers in nineteen cells of different genetic status. C-3 hydroxy and NH groups are responsible contributing groups for their cytotoxicity. Mahanine reduced the doses of cisplatin and paclitaxel in cervical cancer showing better efficacy and useful as an adjunct chemotherapeutic agent to reduce toxicity these two drugs. A new cheap process for this preparation was established. EtOAc extract containing alkaloids enriched with mahanimbine and mahanine, is active against glioma and cervical cancers. Mahanine is targeting the chaperone Hsp90 which led to the proteasome-dependent degradation of several Hsp90-client proteins in diverse carcinoma types, glioblastoma, cervical carcinoma and pancreatic adenocarcinoma irrespective of their tissue origins thereby killing the cancer cells.
    • 本发明涉及两种主要成分,来自Murraya koenigii的mahanine和mahanimbine(dehydroxy-mahanine)用于治疗胶质母细胞瘤和宫颈癌。 Mahanimbine在不同遗传状态的19个细胞中表现出针对淋巴样白血病,骨髓性白血病,神经胶质瘤,宫颈癌,胰腺癌,结肠癌和肺癌的抗癌活性。 C-3羟基和NH基团是它们的细胞毒性的负责贡献组。 Mahanine降低了子宫颈癌中顺铂和紫杉醇的剂量,显示出更好的疗效,作为辅助化疗药物有用,以降低这两种药物的毒性。 建立了一个新的廉价程序,用于此准备工作。 含有富马那霉素和马哈尼碱的生物碱的乙酸乙酯提取物对胶质瘤和宫颈癌有活性。 Mahanine针对分子伴侣Hsp90,导致多种癌症类型,胶质母细胞瘤,宫颈癌和胰腺腺癌中的几种Hsp90-客户蛋白的蛋白酶体依赖性降解,而不管其组织来源如何,从而杀死癌细胞。
    • 5. 发明授权
    • Ferroelectric nanophotonic materials and devices
    • 铁电纳米光子材料和器件
    • US07346248B2
    • 2008-03-18
    • US11497935
    • 2006-08-01
    • Harry A. AtwaterKaushik BhattacharyaKaushik DayalMatthew DickenDemetri PsaltisAxel SchererGuruswami Ravichandran
    • Harry A. AtwaterKaushik BhattacharyaKaushik DayalMatthew DickenDemetri PsaltisAxel SchererGuruswami Ravichandran
    • G02B6/00
    • G02F1/03B82Y20/00G02B6/3574G02F2202/32
    • Systems and methods for manipulating light with tunable ferroelectric photonic devices. Devices having tunable properties that exhibit photonic bandgap behavior are fabricated from ferroelectric materials. Apparatus is provided to apply tuning signals to the ferroelectric material using one or more of electric fields, mechanical forces, optical fields, and thermal fields. Control circuitry is provided to generate the control signals needed to apply the tuning signals. Input and output ports are provided to allow input signals to be received and to provide output signals. In some cases, a feedback loop is provided to use a portion of the output signal as a diagnostic signal for control of the operation of the device within an acceptable range. It is expected that ferroelectric photonic devices operating according to principles of the invention will be useful for a wide variety of applications, including optical switching, optical modulation, optical computing, and performing logic optically.
    • 用可调谐铁电光子器件操纵光的系统和方法。 具有光子带隙特性的具有可调谐特性的器件由铁电材料制成。 提供了使用电场,机械力,光场和热场中的一个或多个来将调谐信号施加到铁电材料的装置。 提供控制电路以产生应用调谐信号所需的控制信号。 提供输入和输出端口以允许接收输入信号并提供输出信号。 在一些情况下,提供反馈回路以使用输出信号的一部分作为用于在可接受范围内控制装置的操作的诊断信号。 期望根据本发明的原理操作的铁电光子器件对于各种应用(包括光学开关,光学调制,光学计算和光学执行逻辑)将是有用的。
    • 6. 发明授权
    • Process for the isolation of organic compounds useful for the treatment of cancer
    • 用于分离可用于治疗癌症的有机化合物的方法
    • US08637679B2
    • 2014-01-28
    • US13416930
    • 2012-03-09
    • Chitra MandalBikas Chandra PalKaushik BhattacharyaSuman Kumar SamantaSayantani SarkarRanjita Das
    • Chitra MandalBikas Chandra PalKaushik BhattacharyaSuman Kumar SamantaSayantani SarkarRanjita Das
    • C07D491/052
    • A61K31/407A61K36/75A61K2236/39C07D491/052
    • The present invention relates to two main components, mahanine and mahanimbine (dehydroxy-mahanine) from Murraya koenigii for the treatment of glioblastoma and cervical carcinoma. Mahanimbine exhibited anti-cancer activity against lymphoid leukemia, myeloid leukemia, glioma, cervical carcinoma, pancreatic, colon and lung cancers in nineteen cells of different genetic status. C-3 hydroxy and NH groups are responsible contributing groups for their cytotoxicity. Mahanine reduced the doses of cisplatin and paclitaxel in cervical cancer showing better efficacy and useful as an adjunct chemotherapeutic agent to reduce toxicity these two drugs. A new cheap process for this preparation was established. EtOAc extract containing alkaloids enriched with mahanimbine and mahanine, is active against glioma and cervical cancers. Mahanine is targeting the chaperone Hsp90 which led to the proteasome-dependent degradation of several Hsp90-client proteins in diverse carcinoma types, glioblastoma, cervical carcinoma and pancreatic adenocarcinoma irrespective of their tissue origins thereby killing the cancer cells.
    • 本发明涉及两种主要成分,来自Murraya koenigii的mahanine和mahanimbine(dehydroxy-mahanine)用于治疗胶质母细胞瘤和宫颈癌。 Mahanimbine在不同遗传状态的19个细胞中表现出针对淋巴样白血病,骨髓性白血病,神经胶质瘤,宫颈癌,胰腺癌,结肠癌和肺癌的抗癌活性。 C-3羟基和NH基团是它们的细胞毒性的负责贡献的组。 Mahanine降低了子宫颈癌中顺铂和紫杉醇的剂量,显示出更好的疗效,作为辅助化疗药物有用,以降低这两种药物的毒性。 建立了一个新的廉价程序,用于此准备工作。 含有富马那霉素和马哈尼碱的生物碱的乙酸乙酯提取物对胶质瘤和宫颈癌有活性。 Mahanine针对分子伴侣Hsp90,导致多种癌症类型,胶质母细胞瘤,宫颈癌和胰腺腺癌中的几种Hsp90-客户蛋白的蛋白酶体依赖性降解,而不管其组织来源如何,从而杀死癌细胞。